Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.

Lucid Diagnostics Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

CONFERENCE CALL AND WEBCAST AT 8:30 AM ET NEW YORK, JULY 31, 2026 /PRNEWSWIRE/ -- PAVMED INC. (NASDAQ: PAVM) ("PAVMED" OR THE "COMPANY"), A DIVERSIFIED COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY, OPERATING IN THE MEDICAL DEVICE, DIAGNOSTICS, AND DIGITAL HEALTH SECTORS, TODAY ANNOUNCED THAT IT WILL HOST A BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON FRIDAY, AUGUST 14, 2026, AT 8:30 AM ET. DURING THE CALL,LISHAN AKLOG, M.D.

PAVMED TO HOLD SECOND QUARTER 2026 BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON AUGUST 14, 2026

CONFERENCE CALL AND WEBCAST AT 8:30 AM ET NEW YORK, JULY 30, 2026 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THAT IT WILL HOST A BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 13, 2026, AT 8:30 AM ET. DURING THE CALL,LISHAN AKLOG, M.D.

LUCID DIAGNOSTICS TO HOLD SECOND QUARTER 2026 BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON AUGUST 13, 2026

VERIS HEALTH PROGRESSED COMMERCIAL EXPANSION AND ADVANCED IMPLANTABLE PHYSIOLOGICAL MONITOR DEVELOPMENT TOWARD FDA SUBMISSION LUCID DIAGNOSTICS CONTINUED BUILDING COMMERCIAL MOMENTUM AND STRENGTHENED ITS BALANCE SHEET AHEAD OF KEY UPCOMING REIMBURSEMENT MILESTONES PAVMED ADVANCED ITS RELAUNCHED MEDICAL DEVICE PORTFOLIO; EVALUATION OF ADDITIONAL ACQUISITION OPPORTUNITIES ONGOING CONFERENCE CALL AND WEBCAST TO BE HELD TODAY, MAY 15, AT 8:30 AM EDT NEW YORK, MAY 15, 2026 /PRNEWSWIRE/ --PAVMED INC.(NASDAQ: PAVM) ("PAVMED" OR THE "COMPANY"), A DIVERSIFIED COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY, OPERATING IN THE MEDICAL DEVICE, DIAGNOSTICS, AND DIGITAL HEALTH SECTORS, TODAY PROVIDED A BUSINESS UPDATE FOR THE COMPANY AND ITS SUBSIDIARIES, LUCID DIAGNOSTICS INC. (NASDAQ: LUCD) ("LUCID") AND VERIS HEALTH INC. ("VERIS"), AND REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. CONFERENCE CALL AND WEBCAST THEWEBCASTWILL TAKE PLACE ON FRIDAY, MAY 15, 2026, AT 8:30 AM AND IS ACCESSIBLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT PAVMED.COM.

PAVMED PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

PROCESSED 3,177 ESOGUARD  TESTS AND RECOGNIZED 1Q26 REVENUE OF $1.3 MILLION, ENDING QUARTER WITH $45 MILLION IN PROFORMA CASH AND A RUNWAY THAT EXTENDS INTO 2027 AND PAST UPCOMING REIMBURSEMENT MILESTONES CONFERENCE CALL AND WEBCAST TO BE HELD TODAY, MAY 14, AT 8:30 AM EDT NEW YORK, MAY 14, 2026 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY") A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM) ("PAVMED"), TODAY PROVIDED A BUSINESS UPDATE FOR THE COMPANY AND REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2026. CONFERENCE CALL AND WEBCAST THE WEBCAST WILL TAKE PLACE ON THURSDAY, MAY 14, 2026, AT 8:30 AM AND WILL BE ACCESSIBLE IN THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT LUCIDDX.COM.

LUCID DIAGNOSTICS PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

CONFERENCE CALL AND WEBCAST AT 8:30 AM ET NEW YORK, MAY 1, 2026 /PRNEWSWIRE/ -- PAVMED INC. (NASDAQ: PAVM) ("PAVMED" OR THE "COMPANY"), A DIVERSIFIED COMMERCIAL-STAGE MEDICAL TECHNOLOGY COMPANY, OPERATING IN THE MEDICAL DEVICE, DIAGNOSTICS, AND DIGITAL HEALTH SECTORS, TODAY ANNOUNCED THAT IT WILL HOST A BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON FRIDAY, MAY 15, 2026, AT 8:30 AM ET. DURING THE CALL,LISHAN AKLOG, M.D.

PAVMED TO HOLD FIRST QUARTER 2026 BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON MAY 15, 2026

CONFERENCE CALL AND WEBCAST AT 8:30 AM ET NEW YORK, APRIL 30, 2026 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY") A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THAT IT WILL HOST A BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON THURSDAY, MAY 14, 2026, AT 8:30 AM ET. DURING THE CALL,LISHAN AKLOG, M.D.

LUCID DIAGNOSTICS TO HOLD FIRST QUARTER 2026 BUSINESS UPDATE CONFERENCE CALL AND WEBCAST ON MAY 14, 2026

NEW YORK, APRIL 24, 2026 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN REGISTERED DIRECT OFFERING OF 18,000,000 COMMON SHARES AT A PURCHASE PRICE OF $1.00 PER SHARE, ANCHORED BY A $15 MILLION INVESTMENT FROM A FUNDAMENTAL INSTITUTIONAL INVESTOR WITH SUPPORT FROM A LARGE EXISTING SHAREHOLDER. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES, WERE APPROXIMATELY $18 MILLION.

LUCID DIAGNOSTICS ANNOUNCES CLOSING OF $18 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

NEW YORK, APRIL 23, 2026 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY, AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN REGISTERED DIRECT OFFERING OF 18,000,000 COMMON SHARES AT A PURCHASE PRICE OF $1.00 PER SHARE, ANCHORED BY A $15M INVESTMENT FROM A FUNDAMENTAL INSTITUTIONAL INVESTOR WITH SUPPORT FROM A LARGE EXISTING SHAREHOLDER. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER ESTIMATED OFFERING EXPENSES, ARE EXPECTED TO BE APPROXIMATELY $18 MILLION.

LUCID DIAGNOSTICS ANNOUNCES $18 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK

NEW YORK, APRIL 9, 2026 /PRNEWSWIRE/ -- LUCID DIAGNOSTICS INC. (NASDAQ: LUCD)("LUCID" OR THE "COMPANY"), A COMMERCIAL-STAGE, CANCER PREVENTION MEDICAL DIAGNOSTICS COMPANY AND SUBSIDIARY OF PAVMED INC. (NASDAQ: PAVM), TODAY ANNOUNCED THAT LISHAN AKLOG, M.D., LUCID'S CHAIRMAN AND CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE ON THURSDAY, APRIL 16, 2026 AT 10:15 AM EDT.

LUCID DIAGNOSTICS TO PARTICIPATE IN FIRESIDE CHAT AT THE 25TH ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE

MEDTECH INDUSTRY VETERAN TO OVERSEE DEVELOPMENT AND COMMERCIALIZATION OF PAVMED'S CURRENT AND FUTURE MEDICAL DEVICE PORTFOLIO. OCTERIS, INC. SUBSIDIARY FORMED TO ADVANCE ENDOSCOPIC ESOPHAGEAL IMAGING TECHNOLOGY RECENTLY LICENSED FROM DUKE UNIVERSITY.

Lucid Diagnostics Inc.

LUCD

Price

Financial Reports

No items found.

Press Releases

Lucid Diagnostics Inc.

LUCD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

LUCD